{"id":55546,"date":"2026-01-27T11:46:35","date_gmt":"2026-01-27T03:46:35","guid":{"rendered":"https:\/\/flcube.com\/?p=55546"},"modified":"2026-01-27T11:46:36","modified_gmt":"2026-01-27T03:46:36","slug":"hanchorbio-partners-with-wuxi-biologics-on-next-gen-fusion-protein-manufacturing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55546","title":{"rendered":"HanchorBio Partners with WuXi Biologics on Next\u2011Gen Fusion Protein Manufacturing"},"content":{"rendered":"\n

HanchorBio, Inc.<\/strong> and WuXi Biologics<\/strong> (HKG:\u202f2269<\/a>) announced a strategic collaboration<\/strong> under which WuXi Biologics will provide integrated end\u2011to\u2011end development and manufacturing services<\/strong> for HanchorBio\u2019s pipeline of next\u2011generation bifunctional and multifunctional fusion proteins<\/strong>, leveraging HanchorBio\u2019s proprietary FBDB platform technology<\/strong>.<\/p>\n\n\n\n

Deal Structure<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Companies<\/strong><\/td>HanchorBio, Inc. (Taiwan) and WuXi Biologics (HKEX:\u202f2269)<\/td><\/tr>
Agreement Type<\/strong><\/td>Strategic collaboration<\/td><\/tr>
Scope<\/strong><\/td>Development and production of multiple next\u2011generation bifunctional\/multifunctional fusion proteins<\/td><\/tr>
Services<\/strong><\/td>Cell line development, process\/bioanalytical method development, formulation development, GMP manufacturing<\/td><\/tr>
Platform<\/strong><\/td>HanchorBio\u2019s FBDB (Fusion protein Drug Discovery and Development) platform<\/td><\/tr>
Financial Terms<\/strong><\/td>Not disclosed<\/td><\/tr>
Strategic Goals<\/strong><\/td>Enhance CMC execution efficiency, accelerate clinical translation, enable scalable global development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Profile & Strategic Rationale<\/h2>\n\n\n\n